alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with butaclamol in 4 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (butaclamol) | Trials (butaclamol) | Recent Studies (post-2010) (butaclamol) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 45 | 0 | 16 |
| 90 | 1 | 2 | 233 | 3 | 2 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | butaclamol (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 0.0023 | |
| D | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0053 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0112 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0034 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Booth, RG; Brown, RL; Bucholtz, EC; Tropsha, A; Wyrick, SD | 1 |
| Iwamoto, ET | 1 |
| Sonsalla, PK; Terleckyj, I | 1 |
4 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and butaclamol
| Article | Year |
|---|---|
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
Topics: Animals; Binding Sites; Binding, Competitive; Brain; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ligands; Models, Molecular; Pyrilamine; Radioligand Assay; Structure-Activity Relationship; Tetrahydronaphthalenes | 1999 |
Evidence for a model of activation of central sigma systems.
Topics: Animals; Benzazepines; Benzomorphans; Butaclamol; Carbazoles; Dopamine Antagonists; Haloperidol; Kinetics; Male; Models, Biological; Motor Activity; Naltrexone; Narcotic Antagonists; Phenazocine; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, sigma; Sulpiride | 1989 |
The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain Diseases; Butaclamol; Carbazoles; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Interactions; Drug Synergism; Guanidines; Ligands; Male; Methamphetamine; Mice; MPTP Poisoning; Neostriatum; Piperidines; Psychotropic Drugs; Pyrimidines; Receptors, Dopamine; Receptors, sigma; Stereoisomerism; Tyrosine 3-Monooxygenase | 1994 |